测量系统性硬化症胃肠道的反应。
Measuring response in the gastrointestinal tract in systemic sclerosis.
机构信息
aUniversity of Michigan, Ann Arbor, Michigan bCedars Sinai Medical Center, Los Angeles, California cUniversity of Utah, Salt Lake City, Utah, USA.
出版信息
Curr Opin Rheumatol. 2013 Nov;25(6):700-6. doi: 10.1097/01.bor.0000434668.32150.e5.
Abstract
PURPOSE OF REVIEW
Gastrointestinal tract (GIT) involvement in systemic sclerosis (scleroderma, SSc) is the most common internal complication. This review discusses the outcome measures to capture GIT involvement in clinical care and trials.
RECENT FINDINGS
Patient-reported outcome measures have been validated (UCLA Scleroderma Clinical Trial Consortium GIT 2.0 and NIH PROMIS scales) in SSc-GIT. Multiple objective measures are available to assess mucosal involvement and motility in GIT. However, these need to be validated in SSc for trials.
SUMMARY
GIT is a common cause of morbidity and has negative impact on quality of life in SSc. Recommendations are given for trial design and evaluation of GIT involvement in SSc.
摘要
目的综述
胃肠道（GI）受累是系统性硬化症（硬皮病，SSc）最常见的内脏并发症。本文讨论了用于临床护理和临床试验中评估 GI 受累的结局指标。
最近发现
患者报告的结局指标已在 SSc-GI 中得到验证（加州大学洛杉矶分校硬皮病临床试验联盟 GIT 2.0 和 NIH PROMIS 量表）。有多种客观指标可用于评估 GI 黏膜受累和运动功能。然而，这些指标需要在 SSc 中进行验证，才能用于临床试验。
总结
GI 是导致发病率的常见原因，对 SSc 的生活质量有负面影响。本文为 SSc 中 GI 受累的临床试验设计和评估提供了建议。
相似文献
1
Measuring response in the gastrointestinal tract in systemic sclerosis.
Curr Opin Rheumatol. 2013 Nov;25(6):700-6. doi: 10.1097/01.bor.0000434668.32150.e5.
2
Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis.
Arthritis Res Ther. 2021 Apr 22;23(1):125. doi: 10.1186/s13075-021-02506-x.
3
Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis.
Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S55-60. Epub 2015 Aug 31.
4
Construct validity of the Patient-Reported Outcomes Measurement Information System gastrointestinal symptom scales in systemic sclerosis.
Arthritis Care Res (Hoboken). 2014 Nov;66(11):1725-30. doi: 10.1002/acr.22337.
5
Longitudinal Assessment of Patient-reported Outcome Measures in Systemic Sclerosis Patients with Gastroesophageal Reflux Disease - Scleroderma Clinical Trials Consortium.
J Rheumatol. 2019 Jan;46(1):78-84. doi: 10.3899/jrheum.180004. Epub 2018 Nov 15.
6
UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract (GIT) 2.0 Reflux Scale Correlates With Impaired Esophageal Scintigraphy Findings in Systemic Sclerosis.
J Rheumatol. 2021 Sep;48(9):1422-1426. doi: 10.3899/jrheum.201283. Epub 2021 Jan 15.
7
Cross-sectional study using the University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Tract Instrument 2.0 (UCLA SCTC GIT 2.0) for gastrointestinal disorders of systemic sclerosis.
J Dermatol. 2024 Oct;51(10):1329-1334. doi: 10.1111/1346-8138.17327. Epub 2024 Jul 4.
8
Evaluation of Patient and Physician Assessments of Gastrointestinal Disease Activity in Systemic Sclerosis.
J Rheumatol. 2023 Apr;50(4):519-525. doi: 10.3899/jrheum.220832. Epub 2022 Nov 15.
9
High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in Systemic Sclerosis.
Semin Arthritis Rheum. 2017 Dec;47(3):403-408. doi: 10.1016/j.semarthrit.2017.05.005. Epub 2017 May 19.
10
Validation of Serbian version of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in 104 patients with systemic sclerosis.
Rheumatol Int. 2017 May;37(5):735-741. doi: 10.1007/s00296-017-3680-y. Epub 2017 Mar 7.
引用本文的文献
1
Characteristics of patients with systemic sclerosis with aspiration: A single-center study.
J Scleroderma Relat Disord. 2025 Sep 11:23971983251370883. doi: 10.1177/23971983251370883.
2
Endothelial function and vascular events in patients with limited cutaneous systemic sclerosis (EFVELSS): a prospective observational study.
Rheumatol Int. 2025 Jul 8;45(7):166. doi: 10.1007/s00296-025-05919-y.
3
An evaluation of autonomic and gastrointestinal symptoms, and gastric emptying, in patients with systemic sclerosis.
J Scleroderma Relat Disord. 2024 Oct 24:23971983241288039. doi: 10.1177/23971983241288039.
4
Serum markers of microbial translocation and intestinal damage in assessment of gastrointestinal tract involvement in systemic sclerosis.
Clin Exp Med. 2024 Sep 19;24(1):225. doi: 10.1007/s10238-024-01466-1.
5
Does therapy with immunosuppressive drugs improve gastrointestinal symptoms in patients with systemic sclerosis?
RMD Open. 2024 Jul 24;10(3):e004333. doi: 10.1136/rmdopen-2024-004333.
6
Severity and impact of digestive impairment perceived by patients with systemic sclerosis: a cross-sectional study.
BMJ Open. 2024 Apr 29;14(4):e083419. doi: 10.1136/bmjopen-2023-083419.
7
Gastric dysrhythmias in patients with early systemic sclerosis: a cross-sectional study.
Rheumatol Adv Pract. 2024 Mar 12;8(2):rkae041. doi: 10.1093/rap/rkae041. eCollection 2024.
8
Validation of the Portuguese Version of the Scleroderma Health Assessment Questionnaire.
Int J Environ Res Public Health. 2023 Nov 14;20(22):7062. doi: 10.3390/ijerph20227062.
9
Adherence to the Mediterranean Diet in Italian Patients With Systemic Sclerosis: An Epidemiologic Survey.
ACR Open Rheumatol. 2024 Jan;6(1):14-20. doi: 10.1002/acr2.11627. Epub 2023 Nov 2.
10
Anti-Gephyrin Antibodies: A Novel Specificity in Patients With Systemic Sclerosis and Lower Bowel Dysfunction.
Arthritis Rheumatol. 2024 Jan;76(1):92-99. doi: 10.1002/art.42667. Epub 2023 Nov 10.
本文引用的文献
1
Associations between a scleroderma-specific gastrointestinal instrument and objective tests of upper gastrointestinal involvements in systemic sclerosis.
Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):57-63. Epub 2013 Jul 22.
2
Management of gastro-oesophageal reflux disease symptoms that do not respond to proton pump inhibitors.
Curr Opin Gastroenterol. 2013 Jul;29(4):431-6. doi: 10.1097/MOG.0b013e328360433c.
3
Review article on current applications and future concepts of capsule endoscopy.
Digestion. 2013;87(2):91-9. doi: 10.1159/000345346. Epub 2013 Jan 10.
4
Oropharyngeal and esophageal swallowing impairments: their association and the predictive value of the modified barium swallow impairment profile and combined multichannel intraluminal impedance-esophageal manometry.
Ann Otol Rhinol Laryngol. 2012 Nov;121(11):738-45. doi: 10.1177/000348941212101107.
5
Endoscopic techniques for small bowel imaging.
Radiol Clin North Am. 2013 Jan;51(1):177-87. doi: 10.1016/j.rcl.2012.09.010.
6
High-resolution Manometry: Esophageal Disorders Not Addressed by the "Chicago Classification".
J Neurogastroenterol Motil. 2012 Oct;18(4):365-72. doi: 10.5056/jnm.2012.18.4.365. Epub 2012 Oct 9.
7
FDG-PET/CT based response-adapted treatment.
Cancer Imaging. 2012 Sep 28;12(2):324-35. doi: 10.1102/1470-7330.2012.9006.
8
Clinical efficacy and randomized clinical trials in dysphagia.
Int J Speech Lang Pathol. 2012 Oct;14(5):443-6. doi: 10.3109/17549507.2012.717966. Epub 2012 Sep 3.
9
Malnutrition in systemic sclerosis.
Rheumatology (Oxford). 2012 Oct;51(10):1747-56. doi: 10.1093/rheumatology/kes160. Epub 2012 Jul 31.
10
Concomitant symptoms itemized in the Reflux Disease Questionnaire are associated with attenuated heartburn response to acid suppression.
Am J Gastroenterol. 2012 Sep;107(9):1354-60. doi: 10.1038/ajg.2012.197. Epub 2012 Jul 10.
Zotero 插件